Avid Bioservices Inc (CDMO)

[hutschi]

Emerging Treatment Strategies in Nonsquamous NSCLC


Published Online: Sep 05,2017


....

PPHM 1501, a randomized, open-label phase II trial, was evaluating the combination of durvalumab (Imfinzi) with or without bavituximab in patients with previously treated metastatic NSCLC.32 However, the trial was suspended. Durvalumab is a human monoclonal antibody that inhibits the binding of PD-L1 to PD-1. Bavituximab is a monoclonal antibody that leads to production of pro-inflammatory cytokines and induction of tumor- specific cytotoxic T-lymphocyte immunity. A previous phase II trial reported 60% improved median OS in patients treated with bavituximab compared with the control arm.
.......

http://www.targetedonc.com/publications/evolving-paradigms/2017/nsclc/emerging-treatment-strategies-in-nonsquamous-nsclc